Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings
2026-05-20 English
FORM 10-Q
Interim / Quarterly Report Q3 2026
2026-05-15 English
8-K - Lunai Bioworks Inc. (0001527728) (Filer)
Regulatory Filings
2026-05-13 English
8-K/A - Lunai Bioworks Inc. (0001527728) (Filer)
Regulatory Filings
2026-05-11 English
8-K - Lunai Bioworks Inc. (0001527728) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 27, 2026, for Lunai Bioworks, Inc. It details the entry into a material definitive agreement, specifically a merger agreement involving the issuance of Series B Convertible Preferred Stock as merger consideration. The document includes detailed descriptions of the merger terms, the patent portfolio involved, and the rights and restrictions of the preferred stock issued. This type of filing is a current report disclosing a significant corporate event (merger and related financing terms) rather than a full annual or quarterly report, earnings release, or proxy statement. It is not a simple announcement or certification but a substantive disclosure of a material definitive agreement. Therefore, the appropriate classification is Capital/Financing Update (CAP), as it relates to financing activities and capital structure changes resulting from the merger and preferred stock issuance.
2026-05-01 English
8-K - Lunai Bioworks Inc. (0001527728) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC by Lunai Bioworks, Inc. It reports the postponement of a Special Meeting of Stockholders originally scheduled for May 4, 2026, to May 8, 2026. The filing discusses proxy materials, voting procedures, and related administrative details. It references the Definitive Proxy Statement on Schedule 14A and includes a press release as an exhibit. The content is focused on an event update and administrative changes related to a shareholder meeting, not a financial report or earnings release. Form 8-K filings are current reports used to announce major events or changes and fall under the category of Regulatory Filings (RNS) as they do not fit into more specific categories like Annual Report, Earnings Release, or Proxy Solicitation. The document length is over 10,000 characters, indicating it is not a brief announcement but a full current report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-04-28 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.